Patient factors |
Younger age in children |
Older age in adults |
Poor performance status |
Glutathione S-transferase M1 null genotype |
Hemochromatosis C282Y allele |
Pre-existing hepatic dysfunction |
Hypoalbuminemia |
Hyperbilirubinemia |
High serum ferritin |
Positive CMV serology |
Elevated plasma transforming growth factor β level |
Hepatitis B or C infection |
History of pancreatitis |
Disease factors |
Thalassemia major |
Advanced malignancy |
Acute leukemia |
Neuroblastoma |
Delayed platelet engraftment |
Presence of acute graft-versus-host disease |
Treatment factors |
Interval between diagnosis and transplantation greater than 13 months |
Allogeneic HCT |
Unrelated donor HCT |
Mismatched donor |
Second or subsequent transplants |
Prior use of gemtuzumab ozogamicin |
Prior use of norethisterone |
Prior abdominal irradiation |
Use of total parenteral nutrition within 30 days before HCT |
High dose cytoreductive therapy |
Conditioning regimen containing busulfan with or without cyclophosphamide |
Conditioning regimen containing fludarabine |
Conditioning regimen containing melphalan |
Total body irradiation |
Graft-versus-host disease prophylaxis with cyclosporin with or without methotrexate |
Use of sirolimus |
Use of tranexamic acid |
Platelet transfusion containing ABO-incompatible plasma |